Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anbenitamab (KN-026) is a bispecific antibody targeting extracellular domains II and IV of human HER2, blocking both ligand-dependent and independent signaling pathways. Its IgG1 Fc fragment activates FcRγIIIa, triggering strong antibody-dependent cell-mediated cytotoxicity (ADCC) and suppressing tumor cell growth. Anbenitamab shows promise for research in HER2-positive metastatic breast cancer (MBC) [1][2].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder |
Description | Anbenitamab (KN-026) is a bispecific antibody targeting extracellular domains II and IV of human HER2, blocking both ligand-dependent and independent signaling pathways. Its IgG1 Fc fragment activates FcRγIIIa, triggering strong antibody-dependent cell-mediated cytotoxicity (ADCC) and suppressing tumor cell growth. Anbenitamab shows promise for research in HER2-positive metastatic breast cancer (MBC) [1][2]. |
Cas No. | 2367012-88-0 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.